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Abstract
Background: The cannabinoid-1 receptor blockers have been proposed in the management of
obesity and obesity-related liver diseases (fatty liver as NAFLD or NASH). Due to increasing
number of patients to be potentially treated and the need to assess the advantage of this treatment
in terms of risk/benefit, we analyze the side events reported during the treatment with rimonabant
by a systematic review and meta-analysis of all randomized controlled studies.
Methods: All published randomized controlled trials using rimonabant versus placebo in adult
subjects were retrieved. Relative risks (RR) with 95% confidence interval for relevant adverse
events and number needed to harm was calculated.
Results: Nine trials (n = 9635) were considered. Rimonabant 20 mg was associated with an
increased risk of adverse event (RR 1.35; 95%CI 1.17-1.56), increased discontinuation rate (RR
1.79; 95%CI 1.35-2.38), psychiatric (RR 2.35; 95%CI 1.66-3.34), and nervous system adverse events
(RR 2.35; 95%CI 1.49-3.70). The number needed to harm for psychiatric adverse events is 30.
Conclusion: Rimonabant is associated with an increased risk of adverse events. Despite of an
increasing interest for its use on fatty liver, the security profile and efficacy it is needs to be carefully
assessed before its recommendation. At present the use of rimonabant on fatty liver cannot be
recommended.
Background
As the consequence of important biologic and social mod-
ifications, in the last century new non-infectious epidemic
diseases appeared as the most important causes of mortal-
ity in worldwide. Among these new epidemic diseases,
obesity gained a leader position since the pathologic accu-
mulation of adipose tissue has important deleterious
effect on life expectancy [1,2]. The metabolic syndrome,
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of which obesity is the most common cause, is considered
the most important risk factor for cardiovascular diseases
and other chronic diseases [3].
The algorithm for the management of obesity includes
non-pharmacologic, pharmacologic and surgery-based
strategies [4]. Several drugs are recommended in the phar-
macological approach and in the last years the cannabi-
noid-1 receptor blocker rimonabant has been proposed as
a potential effective therapeutic approach in the manage-
ment of obesity [5].
Non-alcoholic fatty liver disease (NAFLD), the hepatic
manifestation of the metabolic syndrome [6,7] has been
shown to be present in more that 70% of the obese sub-
jects [8]. There is a consensus that the key mechanism of
hepatic steatosis is the insulin resistance [9]. This observa-
tion prompted to investigate new drugs which may be use-
ful in reducing the fatty content in the liver, the
cornerstone in the treatment of NAFLD [10]. Although
effective, dietary modifications and increased physical
activity are associated with a low rate of compliance in the
real life since recurrence is almost the rule [11,12]. This
explains the increased interest shown by both clinicians
and industry to find pharmacological approaches. Based
on the favorable results of randomized controlled trials
assessing rimonabant in the management of obesity, there
is an increasing interest to assess the efficacy of this drug
in NAFLD. However data of ADAGIO-Lipids trial showed
in NAFLD patients a significant improvement of liver
function test and liver fat [13], the histological evidence
was not evaluated and the two randomized controlled tri-
als on NAFLD [14,15] were stopped prematurely due to
request of national health authorities. Small, uncon-
trolled observations suggested that rimonabant may be an
effective strategy in fatty liver [16] in spite of some adverse
events [17]. The adverse events have been so far analyzed
by meta-analysis of data from Rimonabant In Obesity
(RIO) trials [18,19]. In this review we extend the study on
the side events reported during the treatment with
rimonabant by a systematic review and meta-analysis of
all randomized controlled studies using this cannabinoid-
1 receptor blocker in any pathological condition.
Methods
Criteria for considering studies for this review
We considered all published randomized controlled trials
using rimonabant (any dosage) versus placebo for at least
12 weeks in adults for any clinical indication, regardless of
the language of publication. The outcomes were the
adverse events reported classified as: 1) any adverse event;
2) serious adverse events; 3) discontinuation due to
adverse event; 4) discontinuation due psychiatric adverse
event; and 5) discontinuation due to neurologic adverse
event.
Search methods for identification of studies
Reported randomized clinical trials were identified by
search of The Cochrane Hepato-Biliary Group Controlled
Trials Register (May 2009), The Cochrane Library (Issue 2,
2009), EMBASE (January 1980 to May 2009), and
MEDLINE (January 1966 to May 2009). Search terms were
("rimonabant" OR "Acomplia" OR ["antagonist" AND
"cannabinoid" AND "receptor"]) AND ("randomized
controlled trial" OR "random" OR "blinded" OR "con-
trolled") AND "placebo". The references of all identified
studies were inspected for more trials. We also checked for
any missing trials by examining the references of existing
reviews of this topic.
Two authors (NCT, FTA) independently reviewed the
search output of potentially relevant trials for inclusion
and assessed the trial for inclusion. Studies not meeting
the inclusion criteria were excluded. Disagreements were
settled by discussion with a third co-author (CT). In an
independent manner we assessed the bias risk by the fol-
lowing components of methodological quality of
included studies: generation of allocation sequence, allo-
cation concealment, blinding, incomplete outcome data
and selective outcome reporting [20].
Statistical analysis
We use the software package RevMan 5 [21]. For dichoto-
mous variables, we calculate the relative risk (RR) with
95% confidence interval. A fixed effect model was used
throughout the review, except in the event of significant
heterogeneity between the trials (P < 0.10), when the ran-
dom effect model was chosen. Heterogeneity was
explored by chi-squared test with significance set at P-
value 0.10, and the quantity of heterogeneity was meas-
ured by I2 [22]. We use a funnel plot to explore bias.
Asymmetry in funnel plot of trial size against treatment
effect was used to assess this bias. We perform linear
regression approach described by Egger et al. to determine
the funnel plot asymmetry [23]. Number needed to harm
was calculated.
Results
The initial search strategy included 386 references. Out of
these studies, 26 studies were considered further and 10
randomized controlled trials were finally found suitable
for the analysis [13,24-32]. Out of the 10 trials one was
excluded because no adverse effects were reported (Figure
1) [31].
The characteristics and quality of studies included are
reported in Table 1. All trials had a low risk of bias. Five
trials were designed to assess the efficacy on weight reduc-
tion, one for the percent change of atheroma volume, one
for the management of alcohol dependency, one to assess
the changes in HbA1c; one for hyperandrogenaemia; oneBMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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for change in lipid profile, and one was designed to assess
insulin resistance in patients with polycystic ovary syn-
drome. The last one was the excluded study since the
adverse events were not reported. The longest follow-up
was 24 months with a range between 3 and 24 months. A
pooled 2849 subjects were included in the placebo arm,
2883 in rimonabant 5 mg arm, and 3903 were assigned to
rimonabant 20 mg. In the serious adverse events, discon-
tinuations for adverse events and psychiatric adverse
events analysis biases were observed in the funnel plot
graph (Additional file 1).
Adverse events
The use of rimonabant at dosage of 5 mg was not associ-
ated with any adverse event. Conversely, the use of 20 mg
was associated with an increased risk for adverse event vs.
placebo (RR 1.35; 95%CI 1.17-1.56), with a pooled effect
of increased risk (RR 1.21; 95%CI 1.09-1.34) (Figure 2).
By assessing only serious adverse events, a trend for
increased risk in the rimonabant groups was observed at
both dosages (5 and 20 mg), although the difference did
not reach statistical significance (RR 1.16; 95%CI 0.93-
1.45) (Additional file 2). In the subjects receiving 5 mg
rimonabant, no difference was found in the discontinua-
tion rate for adverse events while in those receiving 20 mg
rimonabant an association between drug use and discon-
tinuation rate (RR 1.79; 95%CI 1.35-2.38) was observed.
The same was found when data obtained in pooled series
(5 and 20 mg of rimonabant) were considered (RR 1.47;
95%CI 1.15-1.87 for) (Figure 3).
By performing a sub-analysis of the psychiatric adverse
events forcing treatment discontinuation we observed
that only rimonabant at dosage of 20 mg was associated
with an increased risk of psychiatric disorders (RR 2.35;
95%CI 1.66-3.34), a difference which remains after pool-
ing both dosages (RR 1.79; 95%CI 1.24-2.58) (Figure 4).
Similarly, 20 mg rimonabant and pooled data of the two
dosages were associated with increased risk for treatment
discontinuation due nervous system adverse events (RR
2.35; 95%CI 1.49-3.70 and, RR 1.89; 95%CI 1.30-2.75,
respectively) (Figure 5).
The analysis of the number needed to harm (NNH) dem-
onstrates a reduced NNH for the occurrence of any
adverse event (NNH 22, for rimonabant 20 mg), and dis-
Flow chart for search strategy and selection of trials Figure 1
Flow chart for search strategy and selection of trials.BMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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Table 1: Methodological quality summary: review authors' judgments about each methodological quality item for each included study.
Author 
(year)
Subjects 
included
Duration
(months)
Primary 
outcome
Adequate 
sequence 
generation
Allocation 
concealment
Blinding Incomplete 
outcome 
data
Selective 
outcome 
reporting
Van Gaal 
(2005)*
placebo = 305 12 Weight change Yes Yes Yes No No
rimonabant 5 
mg = 603
rimonabant 20 
mg = 599
Després 
(2005)*
placebo = 342 12 Weight change Yes Yes Yes No No
rimonabant 5 
mg = 345
rimonabant 20 
mg = 346
Pi-Sunyer 
(2006)*
placebo = 607 12 Weight change Yes Yes Yes No No
rimonabant 5 
mg = 1214
rimonabant 20 
mg = 1219
Scheen 
(2006)*
placebo = 348 12 Weight change Yes Yes Yes No No
rimonabant 5 
mg = 358
rimonabant 20 
mg = 339
Nissen 
(2008)
placebo = 417 18 Change in 
percent 
atheroma 
volume
Yes Yes Yes No No
rimonabant 20 
mg = 422
Van Gaal 
(2008)*
placebo = 168 24 Weight change Yes Yes Yes No No
rimonabant 5 
mg = 363
rimonabant 20 
mg = 305
Soyka (2008) placebo = 127 3 Time to first 
drink
Yes Yes Yes No No
rimonabant 20 
mg = 131
Time to relapse 
to first heavy 
drinking
Rosenstock 
(2008)
Placebo = 140 6 HbA1c NR NR Yes No No
Rimonabant 
20 mg = 138
Després 
(2009)
Placebo = 395 12 Change in HDL 
cholesterol and 
triglycerides
Yes Yes Yes No No
Rimonabant 
20 mg = 404
* The articles with asterisk are part of Rimonabant In Obesity (RIO) trialsBMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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Forest plot graphic assessing the risk to be free of any adverse events at rimonabant dosages of 5 and 20 mg Figure 2
Forest plot graphic assessing the risk to be free of any adverse events at rimonabant dosages of 5 and 20 mg.
Relative risk  Relative risk 
Forest plot graphic assessing the risk to be free of discontinuation due to adverse events at rimonabant dosages of 5 and 20 mg Figure 3
Forest plot graphic assessing the risk to be free of discontinuation due to adverse events at rimonabant dos-
ages of 5 and 20 mg..
Relative risk  Relative risk BMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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continuation due to adverse events (NNH 18, for rimona-
bant 20 mg). It was also found that for every 30 patients
treated with 20 mg rimonabant, one will discontinue the
treatment due to psychiatric adverse events (Table 2).
Discussion
In this study we performed a meta-analysis on the adverse
events related with the treatment with rimonabant, a can-
nabinoid-1 receptor blocker, used primarily in obesity
and related disorders. We observed that the use of rimona-
bant at the dose of 20 mg per day is associated with
adverse events including discontinuation due to psychiat-
ric and neurologic adverse events. These results are similar
to those reported in previous meta-analysis on the
Rimonabant in Obesity (RIO) trials [33]. However our
study included more studies as a trial for alcohol depend-
ence which enrolled subjects without obesity but with
greater risk to present adverse events (particularly psychi-
atric adverse events).
The NNH to discontinuation due to adverse in our study
were similar to other meta-analysis (NNH 14). Of notice
that this NNH is the lowest as compared to other drugs for
obesity treatment (NNH 39, for orlistat; and NNH 500,
for sibutramine). Given the large number of patients eligi-
ble for the treatment with rimonabant, the NNH is a con-
cern [33].
The results of this meta-analysis also suggest that subjects
exposed to 20 mg rimonabant may have some clinically
relevant adverse events, and point to the need that both
patients and investigators should be alerted about the
early detection of these negative events. Since there is no
evidence on the clinical utility and due to the proved evi-
dence of increased adverse events rate, rimonabant cannot
be recommended as a treatment option in NAFLD. This is
further supported by the finding that despite possible
reduction in the hepatic fat content [13], no evidence
regarding histological improvement exists also because of
the premature stop of rimonabant registered trials in
NALFD [14,15], and other diseases (ClinicalTrials.gov reg-
istry: NCT00547118, NCT00678483, NCT00754689,
NCT00434096, NCT00412698, NCT00449605,
NCT00263042, NCT00690456, NCT00228176,
NCT00478972, NCT00478595, NCT00405808,
NCT00458081, NCT00325650, NCT00408148).
Nowadays solid information shows that rather than a
totally benign disease, NAFLD may be a cause of chronic
liver disease with a potential risk to develop end-stage
Forest plot graphic assessing the risk to be free of treatment discontinuation due to psychiatric adverse events at rimonabant  dosages of 5 and 20 mg Figure 4
Forest plot graphic assessing the risk to be free of treatment discontinuation due to psychiatric adverse events 
at rimonabant dosages of 5 and 20 mg.
Relative risk  Relative risk BMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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Forest plot graphic assessing the risk to be free of treatment discontinuation due to neurologic adverse events at rimonabant  dosages of 5 and 20 mg Figure 5
Forest plot graphic assessing the risk to be free of treatment discontinuation due to neurologic adverse events 
at rimonabant dosages of 5 and 20 mg.
Relative risk  Relative risk 
Table 2: Number need to harm (NNH) to each adverse event assessed in the meta-analysis.
Rimonabant treated Event Placebo treated Event CER (%) EER (%) NNH
Any adverse event
Rimonabant 5 mg 2883 2364 1770 1434 81 82 102
Rimonabant 20 mg 3393 2861 2292 1829 80 84 22
Total 6276 5225 4062 3263 80 83 34
Serious adverse events
Rimonabant 5 mg 2883 149 1770 79 4 5 142
Rimonabant 20 mg 3393 207 2292 123 5 6 136
Total 6276 356 4062 202 5 6 143
Discontinuation due to adverse events
Rimonabant 5 mg 2883 232 1770 125 7 8 102
Rimonabant 20 mg 3815 501 2708 206 8 13 18
Total 6698 733 4478 331 7 11 28
Discontinuation due to psychiatric adverse events
Rimonabant 5 mg 2883 81 1770 42 2 3 229
Rimonabant 20 mg 3815 230 2708 72 3 6 30
Total 6698 311 4478 114 3 5 48
Discontinuation due to neurologic adverse events
Rimonabant 5 mg 2883 26 1770 13 1 1 597
Rimonabant 20 mg 3684 78 2581 25 1 2 87
Total 6567 104 4351 38 1 2 141
CER, control event rate; EER, experimental event rate.BMC Gastroenterology 2009, 9:75 http://www.biomedcentral.com/1471-230X/9/75
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liver disease complications that had a deleterious effect in
mortality rates [34]. Considering the short period of time
since its first description, all therapeutic approaches
(pharmacologic or non-pharmacologic, such as dietary)
had not been properly assessed, and the standard of care
of this disease usually follows the guidelines of obesity-
related disorders [35]. During the last 25 years the scien-
tists demonstrate an increased interest in obesity-related
liver complications, and exciting findings about the nox-
ious relationship among the liver and fat tissue were
described [34]. Promote new therapies is one face of the
coin but proper detection of the potential adverse effects
and/or undesirable outcomes must be carefully consid-
ered to be sure to satisfy our goal.
Conclusion
In conclusion the use of rimonabant at 20 mg per day is
associated with clinical adverse events. At present no indi-
cation on the use of this drug on NAFLD exists and there-
fore it cannot be suggested.
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